FFS:....."Amarin failed to meet efficacy and/or conditions sufficient to halt at two separate interims"
We don't know that..... but what we do know is that that Dr. Bhatt,who is an advocate for studies going to completion, is the lead investigator for R-IT.....He was also the lead investigator for Cantos, which went to completion after 6 years and was successful at the completion.....In retrospect, I believe that management never really thought R-IT would be ended early and they consistently announced a very threshold for ending the study at either IA, nor did they really want that result after having been screwed at the Adcom.....They wanted a non-assailable result.